NCT05141669View on ClinicalTrials.gov

Impact of Fingolimod Adherence on Outcomes

CompletedOBSERVATIONAL
Enrollment

694

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

November 20, 2020

Study Completion Date

November 20, 2020

Conditions
Multiple Sclerosis
Interventions
DRUG

Fingolimod

Participants who initiated fingolimod to treat multiple sclerosis (MS)

Trial Locations (1)

07936-1080

Novartis Investigational Site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY